New York, September 18, 2024 - PRISM MarketView - Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced significant software upgrades for its NeuroStar Advanced Therapy system and TrakStar® patient data management platform. These updates are designed to enhance patient care, streamline clinical operations, and strengthen data security for NeuroStar providers.
NeuroStar Advanced Therapy is a noninvasive, outpatient treatment for depression, targeting specific areas of the brain responsible for mood regulation. Unlike traditional antidepressants, which affect the entire body, NeuroStar directly stimulates underactive brain synapses to restore normal function. With over 6.6 million treatments delivered to more than 182,000 patients, NeuroStar has demonstrated an 83% response rate and a 62% remission rate, offering a promising alternative for those who haven’t found relief through medication. Depression rates are reaching all-time highs, with 29% of Americans reporting a depression diagnosis at some point in their lives, according to Gallup.
Key updates include:
- Enhanced Patient Communication: New CRM features automate SMS and email communications, providing personalized guidance and secure insurance card uploads to streamline claims processing.
- Expanded Clinical Surveys: Practices can access a wider range of automated surveys, enabling real-time monitoring of patient well-being and improving tailored care.
- Advanced Data Capture: The NeuroStar system now synchronizes critical clinical data with TrakStar, improving accuracy and automating tracking.
- Improved Security: The proactive operating system updates enhance data security and encryption, safeguarding patient information and communications.
Last month, Neuronetics celebrated the two-year anniversary of NeuroStar University, which has trained over 678 providers, improving patient care and clinical outcomes.
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on X.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities